Clinical TrialAug 11, 2026, 03:04 PM
Theriva Biologics Doses First Patient in Phase IIa VIRAGE2 Trial for PDAC
AI Summary
Theriva Biologics announced financial results for Q2 2026 and provided a business update, highlighting the dosing of the first patient in its Phase IIa VIRAGE2 clinical trial for metastatic pancreatic ductal adenocarcinoma (PDAC). This trial evaluates more frequent dosing of VCN-01 to optimize treatment outcomes. The company also reported a significant reduction in general and administrative expenses by 82% and research and development expenses by 35% year-over-year. Cash and cash equivalents stood at $11.3 million, providing liquidity until Q1 2027.
Key Highlights
- First patient dosed in Phase IIa VIRAGE2 trial for metastatic PDAC.
- VIRAGE2 trial enrollment expected to conclude H2 2026; initial data in Q3 2027.
- Proposed Phase II/III trial design for VCN-01 in retinoblastoma finalized.
- Q2 2026 G&A expenses decreased 82% to $2.0 million from $11.2 million.
- Q2 2026 R&D expenses decreased 35% to $1.3 million from $2.0 million.
- Q2 2026 net loss was $(3.2) million, down from $(13.1) million in Q2 2025.
- Cash and cash equivalents were $11.3 million as of June 30, 2026.
- Liquidity is sufficient until Q1 2027.
Price Impact
More from TOVX